DF
KYMR icon

Dunhill Financial’s Kymera Therapeutics KYMR Stock Holding History

Dunhill Financial’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1
Closed -$62 – 1992
2025
Q4 		$62 Buy
+1
New +$68 ﹤0.01% 1575

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Dunhill Financial's KYMR Position: Q1 2026 in Review

Dunhill Financial sold out of Kymera Therapeutics (KYMR) in Q1 2026, closing a stake of 1 share — an estimated $62 sold.

Dunhill Financial first reported a position in KYMR in Q4 2025 and held it in 1 quarter. The position peaked at $62 in Q4 2025. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Dunhill Financial reported no remaining Kymera Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Dunhill Financial sold 1 Kymera Therapeutics share in Q1 2026, an estimated $62.
  • Dunhill Financial first reported a position in Kymera Therapeutics in Q4 2025 and held it in 1 quarter.
  • Dunhill Financial's Kymera Therapeutics position peaked at $62 in Q4 2025.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Dunhill Financial's 13F filing for Q1 2026, filed 6 May 2026.